Sentiment for Chemocentryx Inc (NASDAQ:CCXI)

Chemocentryx Inc (NASDAQ:CCXI) institutional sentiment increased to 1.59 in Q2 2018. Its up 0.59, from 1 in 2018Q1. The ratio has improved, as 62 active investment managers increased and started new equity positions, while 39 sold and reduced their stakes in Chemocentryx Inc. The active investment managers in our partner’s database reported: 26.37 million shares, up from 24.22 million shares in 2018Q1. Also, the number of active investment managers holding Chemocentryx Inc in their top 10 equity positions was flat from 1 to 1 for the same number . Sold All: 11 Reduced: 28 Increased: 34 New Position: 28.

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $497.68 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It has a 39.88 P/E ratio. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe CrohnÂ’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.

The stock decreased 3.62% or $0.37 during the last trading session, reaching $9.85. About 213,959 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 51.30% since December 8, 2017 and is uptrending. It has outperformed by 35.68% the S&P500.

Bvf Inc Il holds 9.04% of its portfolio in ChemoCentryx, Inc. for 7.03 million shares. P.A.W. Capital Corp owns 85,000 shares or 1.13% of their US portfolio. Moreover, Wasatch Advisors Inc has 0.38% invested in the company for 2.38 million shares. The Connecticut-based Nantahala Capital Management Llc has invested 0.33% in the stock. Spark Investment Management Llc, a New York-based fund reported 163,900 shares.

Since January 1, 0001, it had 0 insider buys, and 7 sales for $88.11 million activity.

ChemoCentryx, Inc. (NASDAQ:CCXI) Ratings Coverage

Ratings analysis reveals 50% of ChemoCentryx’s analysts are positive. Out of 4 Wall Street analysts rating ChemoCentryx, 2 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $12.5 while the high is $20. The stock’s average target of $16.38 is 66.29% above today’s ($9.85) share price. CCXI was included in 4 notes of analysts from June 28, 2018. The company was downgraded on Tuesday, August 14 by JP Morgan. Canaccord Genuity maintained ChemoCentryx, Inc. (NASDAQ:CCXI) rating on Monday, November 12. Canaccord Genuity has “Buy” rating and $20 target.